[Learning from My Experience: Outpatient Care for Cancer Multigene Genomic Testing].


Journal

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
ISSN: 1347-5231
Titre abrégé: Yakugaku Zasshi
Pays: Japan
ID NLM: 0413613

Informations de publication

Date de publication:
2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 12 9 2020
Statut: ppublish

Résumé

We established an outpatient service in November 2017 to provide cancer gene profiling test services to cancer patients. To date, we have seen approximately 100 patients. Our staff includes genetic counselors and nurses specialized in genetic medicine. Our experience highlights the importance of healthcare professionals having in-depth knowledge of cancer therapeutic drugs and/or investigational drugs based on cancer genome medicine. Recently, poly(ADP-ribose) polymerase (PARP) inhibitors have been approved for treating breast cancer patients with germline BRCA mutation; thus, in-depth knowledge of genetics and skills for genetic counseling are often considered indispensable in working with cancer patients. However, because the prompt treatment of clear and present cancer is the top priority in clinical settings, providing genetic information at that time, including that of unaffected family members, is of low priority for most patients who are dealing with the severe side effects of anti-cancer therapies. Pharmacists have an essential role to play in cancer therapeutics, talking with patients in order to assess their condition and to clarify the status of their treatment with anticancer agents. Genetic pharmacists should therefore work closely with genetics nurses and genetic counselors in the clinical practice of cancer genomic medicine. In this symposium, I would like to describe our experience caring for patients through our outpatient service, and to discuss the ideal framework for multidisciplinary cooperation to promote cancer genomic medicine.

Identifiants

pubmed: 32378669
doi: 10.1248/yakushi.19-00217-4
doi:

Substances chimiques

BRAP protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Review

Langues

jpn

Sous-ensembles de citation

IM

Pagination

667-668

Auteurs

Eriko Aimono (E)

Division of Clinical Cancer Genomics, Keio University School of Medicine.

Aki Iguchi (A)

Division of Clinical Cancer Genomics, Keio University School of Medicine.

Kaori Mochida (K)

Division of Clinical Cancer Genomics, Keio University School of Medicine.

Mitsuho Imai (M)

Division of Clinical Cancer Genomics, Keio University School of Medicine.

Hideyuki Hayashi (H)

Division of Clinical Cancer Genomics, Keio University School of Medicine.

Hiroshi Nishihara (H)

Division of Clinical Cancer Genomics, Keio University School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH